Clinical Trials Now Enrolling
ABEMACICLIB PLUS LY3214996 FOR RECURRENT GLIOBLASTOMA
A Phase 0 clinical trial combining Abemaciclib (CDK4/6 inhibitor) and LY3214996 (ERK inhibitor) in recurrent glioblastoma participants scheduled for resection to evaluate central nervous system (CNS) penetration
Visit ClinicalTrials.gov or use NCT identifier NCT04391595 to view inclusion criteria and additional study details.
INFIGRATINIB FOR RECURRENT GLIOBLASTOMA
A Phase 0 study of infigratinib in recurrent high-grade glioma participants with an FGFR gene fusion scheduled for resection to evaluate central nervous system (CNS) penetration with PK triggered expansion cohort
Visit ClinicalTrials.gov or use NCT identifier NCT04424966 to view inclusion criteria and additional study details.
RIBOCICLIB FOR RECURRENT GLIOBLASTOMA
A Phase 0/2 study of ribociclib in preoperative Rb-positive recurrent high-grade glioma patients scheduled for resection
Visit ClinicalTrials.gov or use NCT identifier NCT02933736 to view inclusion criteria and additional study details.
RIBOCICLIB FOR RECURRENT MENINGIOMA
A Phase 0/2 study of ribociclib in preoperative Rb-positive recurrent high-grade meningioma patients scheduled for resection
Visit ClinicalTrials.gov or use NCT identifier NCT02933736 to view inclusion criteria and additional study details.
RIBOCICLIB PLUS EVEROLIMUS FOR RECURRENT GLIOBLASTOMA
A Phase 0/2 study of ribociclib in combination with everolimus in preoperative Rb-intact recurrent high-grade glioma patients scheduled for resection
Visit ClinicalTrials.gov or use NCT identifier NCT03834740 to view inclusion criteria and additional study details.
This list was last updated 11/10/2020
NEW DIAGNOSis?
Ivy Phase 0 clinical trials are currently available for patients whose tumors have recurred and require surgery. If you are a newly-diagnosed brain tumor patient, please feel free to contact us for additional information on current standard-of-care treatments. In the event that your tumor does recur, we will have options. Talk to an Ivy Navigator today to discuss establishing a proactive treatment plan.